Researchers at Penn State University have created a revolutionary hydrogel coating that shields transplanted insulin-producing cells from immune rejection, enabling effective diabetes treatment without immunosuppressive drugs, marking a significant breakthrough in regenerative medicine.
Researchers at Penn State University say they have developed an ultra-thin hydrogel coating that can shield transplanted insulin-producing cells from the immune system, a step that could help diabetes treatment avoid the long-term use of immunosuppressive drugs. The work, published in Nature Biomedical Engineering in August 2026, showed that the treated cells helped diabetic mice regain healthy blood sugar levels and kept most of them diabetes-free for more than 100 days.
The idea draws on a natural structure called the zona pellucida, the transparent outer layer that surrounds human eggs. According to the researchers, the artificial version acts like a microscopic “cloak”, hiding donor cells from immune attack while still allowing insulin and other small molecules to pass through. That balance is crucial: cell therapy can work only if transplanted cells stay alive and functional, but the immune system usually treats donor tissue as a threat.
Yong Wang, a biomedical engineering professor and the study’s lead author, said existing cell therapies can be effective for some diseases, including certain cancers, but diabetes remains harder to treat because transplanted islet cells are often rejected. He said current approaches usually depend on continuous immunosuppressive medication, which can bring serious side effects, including a higher cancer risk. The Penn State team said earlier hydrogel-based encapsulation efforts had not managed to reproduce both the zona pellucida’s fine structure and its protective hardening effect.
The coating itself took eight years to develop, Wang said. The researchers built a hydrogel layer only 20 micrometres thick, thin enough to fit the curved surface of living cells without disrupting their function. After testing its compatibility with tissue, they wrapped insulin-producing pancreatic islets in the coating and transplanted them into diabetic mice. Within a week, the animals’ blood sugar had returned to normal, and most stayed free of diabetes for more than 100 days without ongoing immunosuppression. The team now plans to study how long the protection can last and whether the platform could eventually be adapted for other uses in immunotherapy and regenerative medicine.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
